



## Average FY Product Sales Consensus

€m	2021a	2022e	2023e	2024e	2025e	2026e	2027e	Peak Sales	NPV*
<b>Product Portfolio</b>									
Cimzia	1,841	1,976	2,036	1,940	1,882	1,438	1,214		4,872
Vimpat	1,549	969	619	519	453	399	366		1,697
Keppra	970	752	665	606	564	523	466		2,248
Briviact	355	436	508	571	618	566	384	621	1,632
Neupro	307	280	250	215	194	178	170		706
Evenity**		652	797	938	1,061	1,115	1,091	1,186	2,103
Nayzilam	57	84	107	128	144	147	142	176	497
Bimzelx	4	146	477	933	1,391	1,856	2,341	3,220	8,015
Fintepla		99	253	372	486	587	608	818	2,061
<b>Potential new products**</b>									
Zilucoplan		0	67	188	320	462	566	995	2,430
Rozanolixizumab (Rozimab)		0	42	133	258	411	515	1,159	2,145
Dapimab		0	0	4	51	162	226		
Staccato alprazolam		0	1	17	58	100	140	246	572
Bepranemab		0	0	13	43	63	79		

\* If NPV cell blank: not sufficient data available

\*\*global sales, non-risk adj.

## Median FY Product Sales Consensus

€m	2021a	2022e	2023e	2024e	2025e	2026e	2027e	Peak Sales	NPV*
<b>Product Portfolio</b>									
Cimzia	1,841	1,981	2,050	1,906	1,662	1,398	1,200		4,850
Vimpat	1,549	987	586	516	456	406	386		1,665
Keppra	970	789	683	594	541	490	451		1,945
Briviact	355	437	509	572	625	609	389	641	1,664
Neupro	307	287	256	215	201	185	172		642
Evenity**		668	807	939	1,077	1,119	1,095	1,173	2,240
Nayzilam	57	85	108	127	143	146	140	156	550
Bimzelx	4	150	454	877	1,359	1,832	2,340	3,284	7,814
Fintepla		102	253	366	458	584	632	791	2,000
<b>Potential new products**</b>									
Zilucoplan		0	50	172	332	488	640	1,080	2,335
Rozanolixizumab (Rozimab)		0	32	145	268	352	440	1,080	1,953
Dapimab		0	0	0	50	180	225		
Staccato alprazolam		0	0	18	42	75	118	208	500
Bepranemab		0	0	0	27	27	56		

\* If NPV cell blank: not sufficient data available

\*\*global sales, non-risk adj.

Based on the estimates of 19 brokers

Last updated: 24/03/22